Krispy Kreme plans board overhaul to boost lagging performance
The company is bringing in heavy hitters from the food and beverage industry to help right the ship as its stock price sinks.
Story Highlights Krispy Kreme nominates new board members as stock price sinks.
'Turnaround group' of nominees are food and beverage industry veterans.
Board vote follows recent C-suite changes as company eyes expansion strategy.
Krispy Kreme Inc. (NASDAQ: DNUT) is looking to shake up its board of directors as its share price continues to lag.
Shares of the Charlotte-based doughnut chain fell to $4.30 as of the market's close on April 24. That represents a decline of more than 67% from its 52-week high of $13.25.
The company's efforts to reshape its board include nominations of four new members — and reducing its number of board seats to nine. It has 11 seats currently.
GET TO KNOW YOUR CITY
Find Local Events Near You
Connect with a community of local professionals.
Explore All Events
The new nominees are: Bernardo Hees, former Burger King and Kraft Heinz CEO; Patrick Grismer, former CFO at Starbucks; Easwaran Sundaram, former chief digital and technology officer at Jet Blue; and Gordon von Bretten, a senior partner at JAB Holdings Co.
Six members of Krispy Kreme's board are not up for reelection, including chair Olivier Goudet, a senior investment adviser at German investment partnership JAB.
The nominees would join current board members Josh Charlesworth, also Krispy Kreme's CEO, Marissa Andrada, Patricia Capel, David Deno and Gerhard Pleuhs, who are up for reelection.
'No confidence' vote as Krispy Kreme stock languishes
A vote will take place at the company's annual meeting on June 17. The board is expected to form a strategy and operating committee chaired by nominee Hees following that meeting.
Potential board member von Bretten would be a new representative for JAB. Its subsidiary, JAB Indulgence B.V., held a more than 44% stake of Krispy Kreme as of Aug. 12, according to U.S. Securities and Exchange Commission filings.
JAB acquired Krispy Kreme and took it private in 2016. It launched an initial public offering for the doughnut chain in 2021.
Sweeping changes to the board can be driven by activist shareholders or other catalysts — but Krispy Kreme has not indicated that is a driver, says Andrew Wolf, senior analyst at C.K. King & Associates.
'It's an acknowledgement their execution hasn't been what they want. The stock has really underperformed,' he says. 'It's a no confidence vote from Wall Street.'
Krispy Kreme reported net revenue of $1.67 billion for fiscal 2024, down 1.2% from a year prior. Net income for the year was $3.8 million, compared to a loss of $36.6 million in fiscal 2023. Those results reflect its sale of Insomnia Cookies as well as a cybersecurity incident that disrupted operations and had an estimated $10 million impact.
Recent C-suite changes as company plots expansion moves
The potential board changes come as Krispy Kreme works to reposition the brand and grow into 'a bigger and better Krispy Kreme,' Charlesworth said during the company's quarterly earnings call in February.
The company has overhauled its C-suite, naming four top execs in January. That includes Nicola Steele as chief operating officer, Dave Skena as chief growth officer, Alison Holder as chief product officer, and Raphael Duvivier as president of international.
Charlesworth says Krispy Kreme has adopted a strategy that aims to maximize U.S. expansion through its shops and partnerships with McDonald's, Kroger, Publix and Target.
'An added benefit of this expansion with national partners is the opportunity to identify and close existing underperforming doors, which we expect to do in 2025,' Charlesworth says.
Krispy Kreme operates in 40 countries, with doughnuts available at more than 17,500 access points. Digital sales represented 14.4% of retail sales for the last fiscal year. Krispy Kreme is evaluating refranchising for international markets.
'Our transformation continues in 2025 with clear business priorities that are rooted in our strategy,' Charlesworth says.
'Turnaround group' will determine Krispy Kreme's fate
Krispy Kreme's capital-light international expansion strategy will allow the company to redeploy capital, with the U.S. representing its biggest opportunity for growth. It also will boost the balance sheet and simplify operations, Wolf says.
He referenced Krispy Kreme's contract with McDonald's and those types of partnerships as a potential win.
'The positioning is the opportunity. The execution is where they've been struggling,' Wolf says.
The board nominees are seasoned professionals with significant experience. That signifies that the company recognizes the need for change, says Steven Cox, marketing professor at Queens University's McColl School of Business.
'This is a turnaround group,' he says. 'Highly experienced board members are not inexpensive, but the fate of the company depends upon the actions they take.
A major disadvantage is lack of experience in the doughnut industry — but nominating those with a proven track record could generate fresh ideas, Cox adds.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
18 minutes ago
- Business Wire
PAMT CORP Announces Results for the Second Quarter Ended June 30, 2025
TONTITOWN, Ark.--(BUSINESS WIRE)--PAMT CORP (NASDAQ: PAMT) ('we' or the 'Company') today reported consolidated net loss of $9.6 million, or diluted and basic loss per share of $0.46, for the quarter ended June 30, 2025. These results compare to consolidated net loss of $2.9 million, or diluted and basic loss per share of $0.13, for the quarter ended June 30, 2024. Operating revenues decreased 17.4% to $151.1 million for the second quarter of 2025 when compared to $182.9 million for the second quarter of 2024. Liquidity, Capitalization, and Cash Flow As of June 30, 2025, we had an aggregate of $177.1 million of cash, marketable equity securities, and available liquidity under our line of credit and $244.9 million of stockholders' equity. Outstanding debt was $331.2 million as of June 30, 2025, which represents a $5.7 million increase from December 31, 2024. During the first half of 2025, we generated $17.2 million in operating cash flow. About PAMT CORP PAMT CORP is a holding company that owns subsidiaries engaged in providing truckload dry van carrier services transporting general commodities throughout the continental United States, as well as in the Canadian provinces of Ontario and Quebec. The Company's consolidated operating subsidiaries also provide transportation services in Mexico through its gateways in Laredo and El Paso, Texas, under agreements with Mexican carriers. Forward-Looking Statements Certain information included in this document contains or may contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may relate to expected future financial and operating results, prospects, plans or events, and are thus prospective. Such forward-looking statements are subject to risks, uncertainties and other factors which could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, excess capacity in the trucking industry; surplus inventories; general inflation, recessionary economic cycles and downturns in customers' business cycles; a significant reduction in or termination of the Company's trucking service by a key customer, including as a result of recent or future labor or international trade disruptions; increases or rapid fluctuations in fuel prices, interest rates, fuel taxes, tolls, and license and registration fees; potential economic, business or operational disruptions or uncertainties that may result from any future public health crises; the resale value of the Company's used equipment; the price and availability of new equipment consistent with anticipated acquisitions and replacement plans; increases in compensation for and difficulty in attracting and retaining qualified drivers and owner-operators; increases in insurance premiums and deductible amounts relating to accident, cargo, workers' compensation, health, and other claims; increases in the number or amount of claims for which the Company is self-insured; inability of the Company to continue to secure acceptable financing arrangements; seasonal factors such as harsh weather conditions that increase operating costs; competition from trucking, rail, and intermodal competitors including reductions in rates resulting from competitive bidding; the ability to identify acceptable acquisition candidates, consummate acquisitions, and integrate acquired operations; our ability to develop and implement suitable information technology systems and prevent failures in or breaches of such systems; the impact of pending or future litigation; general risks associated with doing business in Mexico, including, without limitation, exchange rate fluctuations, inflation, import duties, tariffs, quotas, political and economic instability and terrorism; the potential impact of new laws, regulations or policy, including, without limitation, rules regarding the classification of independent contractors as employees, tariffs, import/export, trade and immigration regulations or policies; and other factors, including risk factors, included from time to time in filings made by the Company with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise forward-looking statements, whether due to new information, future events or otherwise. Considering these risks and uncertainties, the forward-looking events and circumstances discussed above and in company filings might not transpire. PAMT CORP Condensed Consolidated Balance Sheets (unaudited) June 30, December 31, 2025 2024 (in thousands) ASSETS Current Assets: Cash and cash equivalents $68,915 $68,060 Trade accounts receivable, net 75,683 79,967 Other receivables 5,136 4,854 Inventories 2,382 2,433 Prepaid expenses and deposits 8,523 11,555 Marketable equity securities 48,384 42,620 Income taxes refundable - 2,281 Total current assets 209,023 211,770 Property and equipment 776,040 836,490 Less: accumulated depreciation 281,194 309,272 Total property and equipment, net 494,846 527,218 Other non-current assets 3,998 2,666 Total Assets $707,867 $741,654 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $30,964 $31,198 Accrued expenses and other liabilities 16,614 14,569 Income taxes payable 1,774 - Current portion of long-term debt 68,827 73,017 Total current liabilities 118,179 118,784 Long-term debt, net of current portion 262,406 252,565 Deferred income taxes 81,790 92,547 Other long-term liabilities 578 250 Total liabilities 462,953 464,146 STOCKHOLDERS' EQUITY Common stock 224 224 Additional paid-in capital 41,274 41,171 Treasury stock, at cost (28,924) (13,996) Retained earnings 232,340 250,109 Total stockholders' equity 244,914 277,508 Total liabilities and stockholders' equity $707,867 $741,654 Expand ____________________________________ 1) Excludes miles driven by third party power only carriers. 2) The Truckload Operations operating ratio has been calculated based upon total operating expenses, net of fuel surcharge, as a percentage of revenue, before fuel surcharge. We used revenue, before fuel surcharge, and operating expenses, net of fuel surcharge, because we believe that eliminating this sometimes volatile source of revenue affords a more consistent basis for comparing our results of operations from period to period. Expand
Business Wire
18 minutes ago
- Business Wire
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the 'Company' or 'Delcath'), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to three individuals whose employment commenced in June 2025. The grants resulted in the right to purchase 52,500 shares of the Company's common stock and are subject to the terms and conditions of the Company's 2023 Inducement Plan ('Plan'). The options were granted on June 30, 2025, the date the Compensation Committee approved the stock option included within the equity inducements and are subject to an exercise price equal to $13.60, the closing price of Delcath's common stock on June 30, 2025. One-third of the options will vest on the first anniversary of the grant date with the remaining two-thirds of the options vesting in equal monthly installments over the following twenty-four months. The options have a ten-year term, and the vesting of the options are subject to the employee's continued employment with Delcath on each vesting date. The above-described awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and granted pursuant to the terms of the Plan. About Delcath Systems, Inc. Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT ® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT. In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.
Business Wire
18 minutes ago
- Business Wire
KBRA Comments on Colony Bankcorp, Inc.'s Proposed Acquisition of TC Bancshares, Inc.
NEW YORK--(BUSINESS WIRE)--On July 23, 2025, Fitzgerald, GA-based Colony Bankcorp, Inc. (NYSE: CBAN) ("Colony"), parent company of Colony Bank, and Thomasville, GA-based TC Bancshares (OTCQX: TCBC) ('TC Bancshares'), parent company of TC Federal Bank, jointly announced that they had entered into a definitive agreement pursuant to which TC Bancshares, Inc. would merge with and into Colony Bankcorp, Inc., and TC Federal Bank would merge with and into Colony Bank. The transaction, valued at $86.1 million (P/TBV: 1.1x), is 80% stock and 20% cash consideration and is expected to close in 4Q25 pending regulatory approval. Under the agreement, Greg Eiford, TC Bancshares' President and CEO, would be joining CBAN as an Executive VP and Chief Community Banking Officer. In our view, the proposed acquisition is in line with Colony's overall growth strategy of expansion into contiguous markets through both acquisitive and organic means. The transaction allows CBAN to expand its footprint in Georgia, notably, in Thomasville and the Savannah MSA, in addition to Tallahasse and Jacksonville, Florida, while providing solid opportunities for commercial growth and expansion of its fee-based business lines and continuing focus on its commitment to community banking. The acquisition is expected to add approximately $571 million in assets to CBAN's balance sheet at close, with proforma $3.8 billion in total assets, $2.4 billion in loans, and $3.1 billion in deposits, as well as adding 4 branch locations. The combined company's pro forma financial projections include strong profitability metrics following the close of the transaction, in part, due to expected cost savings of approximately 33% of TCBC's operating base. In addition to the cost savings, earnings should receive a temporary boost from accretion income, with CBAN reporting an estimated $13.3 million in interest rate marks on the loan portfolio. Regarding credit quality, both institutions have reflected solid asset quality performance over time, including nominal credit loss history, which is underpinned by disciplined underwriting and conservative management teams that have extensive knowledge of operating markets. The proforma loan portfolio is not expected to change materially as both institutions have complementary loan mixes, with investor CRE remaining the largest component at ~32% of total loans (including multifamily), followed by C&I (including owner-occupied CRE) at ~25%, and residential mortgage at 22%. CBAN conducted a review of the loan portfolio (67% of loans) and expects to record a total gross pre-tax credit mark of $4 million (1%) along with a Day 2 CECL adjustment of $2 million in relation to the transaction. With respect to deposit mix, TCBC maintains a deposit base concentrated in interest-bearing deposits resulting in somewhat elevated deposit costs of 2.45%. That said, NIB deposits are solid at 15% of total deposits as of 2Q25. Furthermore, Colony has managed solid capital metrics with a CET1 ratio of 12.3% at 2Q25, and management anticipates this ratio to improve to 12.5% at closing. Overall, we believe that the proposed acquisition complements CBAN's growth strategy, and while there is an inherent level of integration risk involved with any bank M&A transaction, such risk is somewhat mitigated by management's previous M&A integration experience. About KBRA KBRA, one of the major credit rating agencies, is registered in the U.S., EU, and the UK. KBRA is recognized as a Qualified Rating Agency in Taiwan, and is also a Designated Rating Organization for structured finance ratings in Canada. As a full-service credit rating agency, investors can use KBRA ratings for regulatory capital purposes in multiple jurisdictions. Doc ID: 1010527
